x
Filter:
Filters applied
- Molecular Bases of Disease
- Handa, James TRemove Handa, James T filter
Publication Date
Please choose a date range between 2015 and 2019.
Keyword
- ABC transporter1
- aggresome1
- all-trans-retinal (atRAL)1
- blindness1
- cell death1
- cell surface protein1
- chaperone1
- chloride channel1
- cytotoxicity1
- drug action1
- endoplasmic reticulum-associated protein degradation (ERAD)1
- epithelial cell1
- estrogen receptor (ER)1
- high-throughput screen (HTS)1
- multidrug transporter1
- photoreceptor degeneration1
- protein degradation1
- retina1
- retinal degeneration1
- rhodopsin1
- selective estrogen receptor modulator (SERM)1
- vision1
- vitamin A1
Molecular Bases of Disease
2 Results
- Molecular Bases of DiseaseOpen Access
The selective estrogen receptor modulator raloxifene mitigates the effect of all-trans-retinal toxicity in photoreceptor degeneration
Journal of Biological ChemistryVol. 294Issue 24p9461–9475Published online: May 9, 2019- Tamar Getter
- Susie Suh
- Thanh Hoang
- James T. Handa
- Zhiqian Dong
- Xiuli Ma
- and others
Cited in Scopus: 6The retinoid cycle is a metabolic process in the vertebrate retina that continuously regenerates 11-cis-retinal (11-cisRAL) from the all-trans-retinal (atRAL) isomer. atRAL accumulation can cause photoreceptor degeneration and irreversible visual dysfunction associated with incurable blinding retinal diseases, such as Stargardt disease, retinitis pigmentosa (RP), and atrophic age-related macular degeneration (AMD). The underlying cellular mechanisms leading to retinal degeneration remain uncertain, although previous studies have shown that atRAL promotes calcium influx associated with cell apoptosis. - Cell BiologyOpen Access
Rescuing Trafficking Mutants of the ATP-binding Cassette Protein, ABCA4, with Small Molecule Correctors as a Treatment for Stargardt Eye Disease
Journal of Biological ChemistryVol. 290Issue 32p19743–19755Published online: June 19, 2015- Inna Sabirzhanova
- Miquéias Lopes Pacheco
- Daniele Rapino
- Rahul Grover
- James T. Handa
- William B. Guggino
- and others
Cited in Scopus: 39Background: Mutations in nucleotide binding domain 1 of ABCA4 cause Stargardt Disease.Results: Correctors rescue trafficking of NBD1 mutants by altering a proteostatic network of quality control proteins.Conclusion: Rescue of trafficking ABCA 4 mutants can be accomplished by correctors similar to CFTR.Significance: There is currently no treatment for Stargardt macular degeneration.